Pelubio® is a non-selective nonsteroidal anti–inflammatory drug (NSAID), the active ingredient of which is pelubiprofen - a derivative of arylpropionic acid.
Pelubiprofen has analgesic, anti-inflammatory and antipyretic effects. Analgesic effect is most pronounced in inflammatory pain.
Indications for use
Symptomatic treatment of osteoarthritis
rheumatoid arthritis
back pain
The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of application, does not affect the progression of the disease.
Vacation conditions
They are released by prescription.
Instructions for the medical use of the drug Pelubio® RU LP-007713 from 12/21/2021.
Pelubio® is a prodrug of nonselective cyclooxygenase (COX) inhibitors, has greater selectivity to COX-2 and inhibits IkB kinase-β (IKK-β), an enzyme complex involved in the propagation of the cellular response to inflammation (NF-kB signaling pathway)1-3.
Pelubiprofen is a derivative of 2-arylpropionic acid, capable, in addition to inhibiting COX, to inhibit the chemotactic activation of neutrophils and monocytes induced by the complement component C5a, which is observed in rheumatoid arthritis and other diseases4.
Composition per tablet:
Active substance: pelubiprofen - 30.0 mg
The mechanism of action of pelubiprofen is due to the indiscriminate inhibition of enzymes – cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2), leading to inhibition of the synthesis of prostaglandins – mediators of pain, inflammation and hyperthermic reaction.
Pelubiprofen has analgesic, anti-inflammatory and antipyretic effects. Analgesic effect is most pronounced in inflammatory pain.
Pharmacokinetics
Suction
After ingestion, the drug is absorbed quickly. The influence of food practically does not affect the parameters of pharmacokinetics.
The maximum concentration is reached within 2 hours.
Distribution
Rapid distribution in the liver and kidneys.
Pelubiprofen and its metabolites bind to plasma proteins by 93.3-98.9%.
With repeated administration at a dose of 60 mg three times a day for 7 days, accumulation of pelubiprofen and its metabolites in blood plasma was not observed.
Indications for use
Pelubio® is indicated for use in therapy:
Osteoarthritis
Rheumatoid arthritis
Back pain.
The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of application, does not affect the progression of the disease.
Method of administration and dosage
Inside after eating.
Release form
Tablets of 30 mg.
20 or 30 tablets per pack.
Expiration date
3 years.
Vacation conditions
They are released by prescription.
Shin JS, Baek SR, Sohn SI, Cho YW, Lee KT. Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF-κB inactivation. J Cell Biochem. 2011;112:3594–3603.
Choi IA, Baek HJ, Cho CS, et al. Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC Musculoskelet Disord. 2014 Nov 18;15:375.
Häcker H, Karin M (October 2006). "Regulation and function of IKK and IKK-related kinases". Sci. STKE. 2006 (357): re13.
Instructions for the medical use of the drug Pelubio® RU LP-007713 from 12/21/2021.
Информация в разделе предназначена исключительно для медицинских работников.
Подтвердите, пожалуйста, являетесь ли Вы медицинским работником.
Если Вы не являетесь медицинским работником, пожалуйста, покиньте данный раздел сайта.
